Feb. 10 at 11:57 AM
$ABCL Why consider buying ABCL? Thanks to their AI, this company is able to identify a drug faster than almost anyone. During COVID they discovered Bamlanivimab for Eli Lilly in just 11 days. They screened 5 million cells and identified 500 unique sequence. The drug went from discovery to human clinical trials in just 3 months and was approved by the FDA in 8 months. Such process usually takes 5-10 years.
They use credit card chips to screen millions of B cells. Their AI predicts which sequence is most developable to prevent failure during manufacturing.
They have full backing of the Canadian government with several grants totaling about
$295 million. They have almost
$1.3 billion in total assets and are debt free. They started developing their own drugs and within 6 months we will hear something about their most important trial ABCL365 to help with hot flashes caused by menopause (VMS market) is estimated at
$17 billion/yr and will grow to
$21 billion by 2030.
